WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
pCIS25DTR and L5	3

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L6

Refine Search

Recall Text | Clear

Search History

DATE: Tuesday, December 09, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L6	pCIS25DTR and L5	3	L6
L5	L4 and 293S cells	428276	L5
L4	l3 and vector	117377	L4
L3	cell line production	2344527	L3
L2	5952198.pn.	1	L2
L1	6358703.pn.	1	L1

END OF SEARCH HISTORY

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3   SEP 09   CA/CAplus records now contain indexing from 1907 to the
                    present
 NEWS  4   AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                    August 1, 2003
 NEWS  5   AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6   AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7   AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8   AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                    Truncation
 NEWS  9   AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10   SEP 22   DIPPR file reloaded
 NEWS 11   DEC 08   INPADOC: Legal Status data reloaded
 NEWS 12   SEP 29   DISSABS now available on STN
 NEWS 13   OCT 10   PCTFULL: Two new display fields added
 NEWS 14   OCT 21   BIOSIS file reloaded and enhanced
 NEWS 15   OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS 16   NOV 24   MSDS-CCOHS file reloaded
 NEWS 17   DEC 08   CABA reloaded with left truncation
 NEWS 18   DEC 08   IMS file names changed
 NEWS 19   DEC 09   Experimental property data collected by CAS now available
                    in REGISTRY
 NEWS 20   DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus

 NEWS EXPRESS   NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
                MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
                AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:50:14 ON 09 DEC 2003

=> file medline, uspatful, biosis, dgene, embase, wpids, fsta, jicst, japio,
biobusiness, scisearch, hcaplus
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.21        0.21

FILE 'MEDLINE' ENTERED AT 13:50:51 ON 09 DEC 2003

FILE 'USPATFULL' ENTERED AT 13:50:51 ON 09 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'DGENE' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOBUSINESS' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'SCISEARCH' ENTERED AT 13:50:51 ON 09 DEC 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'HCAPLUS' ENTERED AT 13:50:51 ON 09 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s cell line production
   6 FILES SEARCHED...
L1          307 CELL LINE PRODUCTION

=> s hkb11 cells
L2           16 HKB11 CELLS

=> s 293S cells
L3          253 293S CELLS

=> s pcis25dtr
L4            7 PCIS25DTR

=> s l1 and l2
L5            0 L1 AND L2

=> s l1 and l3
L6            0 L1 AND L3

=> s l1 and l4
L7            0 L1 AND L4

=> s protein expression
```

```
   4 FILES SEARCHED...
L8      336750 PROTEIN EXPRESSION

=> s l8 and l2
L9            8 L8 AND L2

=> s l8 and l3
L10          66 L8 AND L3

=> d l9 ti abs ibib tot

L9   ANSWER 1 OF 8     MEDLINE on STN
TI   Versatile expression system for rapid and stable production of recombinant
     proteins.
AB   Previously we reported the development of a novel expression system with
     Tat/TAR-oriP vectors and HKB11 cell line, which supports high level
     protein expression (Cho et al.  Cytotechnology 2001, 37,
     23-30).  In the present study, we further demonstrated that HKB11
     cells are suitable for high throughput expression (microgram
     scale) of genomic candidates in transient transfection system for in vitro
     evaluation of biological functions.  HKB11 cells were
     also shown to support the production of milligram to gram quantities of
     protein drug candidates for in vivo evaluation of efficacy in various
     disease models.  Stable HKB11 clones secreting high levels of a tissue
     factor (TF; 40-50 pg/c/d) and B-domain deleted recombinant factor VIII
     (BDDrFVIII; 5-10 microU/c/d) were derived under serum-free conditions.
     The specific productivity for these two proteins from the HKB11
     cells was 10-fold greater than those from CHO cells derived under
     the similar conditions.  In conclusion, we have demonstrated that the
     HKB11 cell line is well-suited for transient and long-term production of
     recombinant proteins.
ACCESSION NUMBER:    2003124037     MEDLINE
DOCUMENT NUMBER:     22461258   PubMed ID: 12573030
TITLE:               Versatile expression system for rapid and stable production
                     of recombinant proteins.
AUTHOR:              Cho M-S; Yee H; Brown C; Mei B; Mirenda C; Chan S
CORPORATE SOURCE:    Molecular and Cell Biology, Process Sciences, Bayer
                     Biotechnology, 800 Dwight Way, Berkeley, California
                     94701-1086, USA.
SOURCE:              BIOTECHNOLOGY PROGRESS, (2003 Jan-Feb) 19 (1) 229-32.
                     Journal code: 8506292. ISSN: 8756-7938.
PUB. COUNTRY:        United States
DOCUMENT TYPE:       (EVALUATION STUDIES)
                     Journal; Article; (JOURNAL ARTICLE)
                     (VALIDATION STUDIES)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
ENTRY MONTH:         200310
ENTRY DATE:          Entered STN: 20030318
                     Last Updated on STN: 20031008
                     Entered Medline: 20031007

L9   ANSWER 2 OF 8  USPATFULL on STN
TI     Enhanced transfection system
AB     A mammalian cell gene expression vector system comprising (a) an
       episomal maintenance system (b), a strong promoter/enhancer, (c) a
       protein transactivation system and (d) DNA coding for a heterologous
       protein. The episomal maintenance and protein transactivation systems
       can include sub-elements located on the same or different plasmids
       within the cell expression system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2003:86336  USPATFULL
TITLE:                  Enhanced transfection system
```

INVENTOR(S): Cho, Myung-Sam, Pinole, CA, UNITED STATES
Yee, Helena, San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059942	A1	20030327
APPLICATION INFO.:	US 2001-956576	A1	20010918 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Melissa A. Shaw, Senior Patent Counsel, Bayer Corporation, 800 Dwight Way, Berkeley, CA, 94710
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 8 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Versatile expression system for rapid and stable production of recombinant proteins.
AB Previously we reported the development of a novel expression system with Tat/TAR-oriP vectors and HKB11 cell line, which supports high level **protein expression** (Cho et al. Cytotechnology 2001, 37, 23-30). In the present study, we further demonstrated that **HKB11 cells** are suitable for high throughput expression (microgram scale) of genomic candidates in transient transfection system for in vitro evaluation of biological functions. **HKB11 cells** were also shown to support the production of milligram to gram quantities of protein drug candidates for in vivo evaluation of efficacy in various disease models. Stable HKB11 clones secreting high levels of a tissue factor (TF; 40-50 pg/c/d) and B-domain deleted recombinant factor VIII (BDDrFVIII; 5-10 muU/c/d) were derived under serum-free conditions. The specific productivity for these two proteins from the **HKB11 cells** was 10-fold greater than those from CHO cells derived under the similar conditions. In conclusion, we have demonstrated that the HKB11 cell line is well-suited for transient and long-term production of recombinant proteins.
ACCESSION NUMBER: 2003:150324 BIOSIS
DOCUMENT NUMBER: PREV200300150324
TITLE: Versatile expression system for rapid and stable production of recombinant proteins.
AUTHOR(S): Cho, M.-S. [Reprint Author]; Yee, H.; Brown, C.; Mei, B.; Mirenda, C.; Chan, S.
CORPORATE SOURCE: Molecular and Cell Biology, Process Sciences, Bayer Biotechnology, 800 Dwight Way, Berkeley, CA, 94701-1086, USA
SOURCE: Biotechnology Progress, (January-February 2003) Vol. 19, No. 1, pp. 229-232. print.
CODEN: BIPRET. ISSN: 8756-7938.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Mar 2003
Last Updated on STN: 19 Mar 2003

L9 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of **protein expression** in mammalian cells.
AB A mammalian gene expression vector based on cytomegalovirus (CMV) enhancer/promoter (CMVe/p) for the regulation of gene expression was further optimized by adding oriP elements derived from Epstein-Barr virus (EBV) and the Tat/TAR transactivation axis from human immunodeficiency virus type 1 (HIV-1). Using the Tat/TAR-oriP expression vector, a transient transfection system was optimized for an extended culture period

to produce large amounts of secreted IL-2SA (an IL-2 mutein) in **HKB11 cells**. We observed a 4-fold increase in IL-2SA expression in cells transfected with vectors containing the HIV-1 transactivation axis (Tat/TAR) or oriP elements alone when compared to cells transfected with the control vector having a CMVe/p. Cells transfected with expression vectors equipped with both oriP and Tat/TAR showed an 18-fold increase in IL-2SA expression. This transient transfection system maintained high secretion of IL-2SA for a period of 10-day with no appreciable loss in expression. We demonstrate that during this 10-day culture period, it was possible to produce 1-100 mg of proteins using 500 mug of plasmid DNA.

ACCESSION NUMBER: 2002:470945 BIOSIS
DOCUMENT NUMBER: PREV200200470945
TITLE: An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of **protein expression** in mammalian cells.
AUTHOR(S): Cho, Myung-Sam [Reprint author]; Yee, Helena; Brown, Colleen; Jeang, Kuan-Teh; Chan, Sam
CORPORATE SOURCE: Molecular and Cell Biology, Process Sciences, Biotechnology, Bayer Corporation, Berkeley, CA, USA myung-sam.cho.b@bayer.com
SOURCE: Cytotechnology, (2001 (2002)) Vol. 37, No. 1, pp. 23-30. print.
ISSN: 0920-9069.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Sep 2002
Last Updated on STN: 4 Sep 2002

L9 ANSWER 5 OF 8 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Versatile expression system for rapid and stable production of recombinant proteins
AB Previously we reported the development of a novel expression system with Tat/TAR-oriP vectors and HKB11 cell line, which supports high level **protein expression** (Cho et al. Cytotechnology 2001, 37, 23-30). In the present study, we further demonstrated that **HKB11 cells** are suitable for high throughput expression (microgram scale) of genomic candidates in transient transfection system for in vitro evaluation of biological functions. **HKB11 cells** were also shown to support the production of milligram to gram quantities of protein drug candidates for in vivo evaluation of efficacy in various disease models. Stable HKB11 clones secreting high levels of a tissue factor (TF; 40-50 pg/c/d) and B-domain deleted recombinant factor VIII (BDDrFVIII; 5-10 muU/c/d) were derived under serum-free conditions. The specific productivity for these two proteins from the **HKB11 cells** was 10-fold greater than those from CHO cells derived under the similar conditions. In conclusion, we have demonstrated that the HKB11 cell line is well-suited for transient and long-term production of recombinant proteins.

ACCESSION NUMBER: 2003:171497 SCISEARCH
THE GENUINE ARTICLE: 645JU
TITLE: Versatile expression system for rapid and stable production of recombinant proteins
AUTHOR: Cho M S (Reprint); Yee H; Brown C; Mei B; Mirenda C; Chan S
CORPORATE SOURCE: Bayer Biotechnol, Mol & Cell Biol Proc Sci, 800 Dwight Way, Berkeley, CA 94701 USA (Reprint); Bayer Biotechnol, Mol & Cell Biol Proc Sci, Berkeley, CA 94701 USA
COUNTRY OF AUTHOR: USA
SOURCE: BIOTECHNOLOGY PROGRESS, (JAN-FEB 2003) Vol. 19, No. 1, pp. 229-232.
Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA.
ISSN: 8756-7938.

DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 13
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 6 OF 8 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of **protein expression** in mammalian cells
AB A mammalian gene expression vector based on cytomegalovirus (CMV) enhancer/promoter (CMVe/p) for the regulation of gene expression was further optimized by adding oriP elements derived from Epstein-Barr virus (EBV) and the Tat/TAR transactivation axis from human immunodeficiency virus type 1 (HIV-1). Using the Tat/TAR-oriP expression vector, a transient transfection system was optimized for an extended culture period to produce large amounts of secreted IL-2SA (an IL-2 mutein) in **HKB11 cells**. We observed a 4-fold increase in IL-2SA expression in cells transfected with vectors containing the HIV-1 transactivation axis (Tat/TAR) or oriP elements alone when compared to cells transfected with the control vector having a CMVe/p. Cells transfected with expression vectors equipped with both oriP and Tat/TAR showed an 18-fold increase in IL-2SA expression. This transient transfection system maintained high secretion of IL-2SA for a period of 10-day with no appreciable loss in expression. We demonstrate that during this 10-day culture period, it was possible to produce 1-100 mg of proteins using 500 mug of plasmid DNA.
ACCESSION NUMBER: 2002:588678 SCISEARCH
THE GENUINE ARTICLE: 572FA
TITLE: An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of **protein expression** in mammalian cells
AUTHOR: Cho M S (Reprint); Yee H; Brown C; Jeang K T; Chan S
CORPORATE SOURCE: Bayer Corp, Mol & Cell Biol Proc Sci Biotechnol, Berkeley, CA USA (Reprint); NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA
COUNTRY OF AUTHOR: USA
SOURCE: CYTOTECHNOLOGY, (JUL-AUG 2001) Vol. 37, No. 1, pp. 23-30. Publisher: KLUWER ACADEMIC PUBL, VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS. ISSN: 0920-9069.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 17
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Versatile Expression System for Rapid and Stable Production of Recombinant Proteins
AB Previously we reported the development of a novel expression system with Tat/TAR-oriP vectors and HKB11 cell line, which supports high level **protein expression** (Cho et al. Cytotechnol. 2001, 37, 23-30). In the present study, we further demonstrated that **HKB11 cells** are suitable for high throughput expression (microgram scale) of genomic candidates in transient transfection system for in vitro evaluation of biol. functions. **HKB11 cells** were also shown to support the prodn. of milligram to gram quantities of protein drug candidates for in vivo evaluation of efficacy in various disease models. Stable HKB11 clones secreting high levels of a tissue factor (TF; 40-50 pg/c/d) and B-domain deleted recombinant factor VIII (BDDrFVIII; 5-10 .mu.U/c/d) were derived under serum-free conditions. The specific productivity for these two proteins from the **HKB11 cells** was 10-fold greater than those from CHO cells derived under the similar conditions. In conclusion, we have demonstrated that the HKB11 cell line is well-suited for transient and long-term prodn. of recombinant proteins.

ACCESSION NUMBER: 2002:951572 HCAPLUS
DOCUMENT NUMBER: 138:152354
TITLE: Versatile Expression System for Rapid and Stable Production of Recombinant Proteins
AUTHOR(S): Cho, M.-S.; Yee, H.; Brown, C.; Mei, B.; Mirenda, C.; Chan, S.
CORPORATE SOURCE: Molecular and Cell Biology, Process Sciences, Bayer Biotechnology, Berkeley, CA, 94701-1086, USA
SOURCE: Biotechnology Progress (2003), 19(1), 229-232
CODEN: BIPRET; ISSN: 8756-7938
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS on STN
TI An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of **protein expression** in mammalian cells
AB A mammalian gene expression vector based on cytomegalovirus (CMV) enhancer/promoter (CMVe/p) for the regulation of gene expression was further optimized by adding oriP elements derived from Epstein-Barr virus (EBV) and the Tat/TAR transactivation axis from human immunodeficiency virus type 1 (HIV-1). Using the Tat/TAR-oriP expression vector, a transient transfection system was optimized for an extended culture period to produce large amts. of secreted IL-2SA (an IL-2 mutein) in **HKB11 cells**. The authors obsd. a 4-fold increase in IL-2SA expression in cells transfected with vectors contg. the HIV-1 transactivation axis (Tat/TAR) or oriP elements alone when compared to cells transfected with the control vector having a CMVe/p. Cells transfected with expression vectors equipped with both oriP and Tat/TAR showed an 18-fold increase in IL-2SA expression. This transient transfection system maintained high secretion of IL-2SA for a period of 10-day with no appreciable loss in expression. During this 10-day culture period, it was possible to produce 1-100 mg of proteins using 500 .mu.g of plasmid DNA.
ACCESSION NUMBER: 2002:502219 HCAPLUS
DOCUMENT NUMBER: 138:84087
TITLE: An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of **protein expression** in mammalian cells
AUTHOR(S): Cho, Myung-Sam; Yee, Helena; Brown, Colleen; Jeang, Kuan-Teh; Chan, Sam
CORPORATE SOURCE: Molecular and Cell Biology, Process Sciences, Biotechnology, Bayer Corporation, Berkeley, CA, USA
SOURCE: Cytotechnology (2001), 37(1), 23-30
CODEN: CYTOER; ISSN: 0920-9069
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:50:14 ON 09 DEC 2003)

FILE 'MEDLINE, USPATFULL, BIOSIS, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, JAPIO, BIOBUSINESS, SCISEARCH, HCAPLUS' ENTERED AT 13:50:51 ON 09 DEC 2003
L1 307 S CELL LINE PRODUCTION

```
L2            16 S HKB11 CELLS
L3           253 S 293S CELLS
L4             7 S PCIS25DTR
L5             0 S L1 AND L2
L6             0 S L1 AND L3
L7             0 S L1 AND L4
L8        336750 S PROTEIN EXPRESSION
L9             8 S L8 AND L2
L10           66 S L8 AND L3

=> d l10 and l4
L4 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l10 and l4
L11            1 L10 AND L4

=> d l11 ti abs ibib tot

L11  ANSWER 1 OF 1  USPATFULL on STN
TI     Vectors having terminal repeat sequence of Epstein-Barr virus
AB     The use of a unique terminal repeat sequence derived from Epstein-Barr
       virus to improve the integration frequency of heterologous expression
       vectors in transfected cells is described. The vectors can be used in a
       process for deriving high producing cell lines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2001:13966  USPATFULL
TITLE:                   Vectors having terminal repeat sequence of Epstein-Barr
                         virus
INVENTOR(S):             Cho, Myung-Sam, Pinole, CA, United States
                         Chan, Sham-Yuen, El Sobrante, CA, United States
PATENT ASSIGNEE(S):      Bayer Corporation, Pittsburgh, PA, United States (U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 6180108          B1   20010130
APPLICATION INFO.:       US 1998-209915           19981210  (9)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            Granted
PRIMARY EXAMINER:        Salimi, Ali R.
NUMBER OF CLAIMS:        9
EXEMPLARY CLAIM:         1,3
NUMBER OF DRAWINGS:      3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT:              310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 13:50:14 ON 09 DEC 2003)

     FILE 'MEDLINE, USPATFULL, BIOSIS, DGENE, EMBASE, WPIDS, FSTA,
     JICST-EPLUS, JAPIO, BIOBUSINESS, SCISEARCH, HCAPLUS' ENTERED AT 13:50:51
     ON 09 DEC 2003
L1           307 S CELL LINE PRODUCTION
L2            16 S HKB11 CELLS
L3           253 S 293S CELLS
L4             7 S PCIS25DTR
L5             0 S L1 AND L2
L6             0 S L1 AND L3
L7             0 S L1 AND L4
L8        336750 S PROTEIN EXPRESSION
```

```
L9              8 S L8 AND L2
L10            66 S L8 AND L3
L11             1 S L10 AND L4

=> s l1  and human
   8 FILES SEARCHED...
L12          104 L1 AND HUMAN

=> s l12 and l8
L13           17 L12 AND L8

=> s l13 and l3
L14            0 L13 AND L3

=> s l13 and l2
L15            0 L13 AND L2

=> s l13 and l4
L16            0 L13 AND L4

=> d l13 ti abs ibib tot

L13  ANSWER 1 OF 17  USPATFULL on STN
TI     Lentiviral vector particles resistant to complement inactivation
AB     The present invention provides a retroviral gene delivery system that
       resists complement inactivation through the incorporation of a
       complement regulatory protein into retroviral particles. In particular,
       the present invention provides a lentiviral packaging system comprising
       at least two vectors: a first vector which comprises a nucleotide
       sequence comprising a gag, a pol, or gag and pol genes; and a second
       vector which comprises a nucleotide sequence comprising a gene that
       encodes a complement regulatory protein (CRP) and, optionally, a gene
       that encodes a heterologous or functionally modified envelope protein.
       The genes encoding a heterologous or functionally modified envelope
       protein and a CRP are provided either together in a second nucleotide
       sequence, or separately in second and third nucleotide sequences.
       Producer cells comprising the packaging constructs of the present
       invention and a transgene can be used to produce recombinant retroviral
       particles for transgene delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2003:294430  USPATFULL
TITLE:                    Lentiviral vector particles resistant to complement
                          inactivation
INVENTOR(S):              Schauber, Cherylene A., San Francisco, CA, UNITED
                          STATES
                          Pacheco, Christopher D., Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S):       CELL GENESYS, INC. (U.S. corporation)

                               NUMBER        KIND    DATE
                          --------------- ------ --------
PATENT INFORMATION:       US 2003207445       A1   20031106
APPLICATION INFO.:        US 2003-425323      A1   20030429  (10)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2002-376767P    20020501 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     Karen S. Canady, Esq., Gates & Cooper LLP, Howard
                          Hughes Center, 6701 Center Drive West, Suite 1050, Los
                          Angeles, CA, 90045
NUMBER OF CLAIMS:         24
EXEMPLARY CLAIM:          1
```

NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 17 USPATFULL on STN
TI Pseudotyped retroviral vectors
AB The present invention provides pseudotyped retroviral vectors and packaging systems and methods of using such vectors for retroviral-mediated gene transfer. In particular, the present invention provides a retroviral packaging system that comprises at least two vectors: a first vector comprising a gag, a pol, or gag and pol genes; and a second vector comprising a functionally modified or heterologous envelope gene, for example, a baculovirus envelope gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:294423 USPATFULL
TITLE: Pseudotyped retroviral vectors
INVENTOR(S): Schauber, Cherylene Oas, San Francisco, CA, UNITED STATES
Pacheco, Christopher D., Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): CELL GENESYS, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207438	A1	20031106
APPLICATION INFO.:	US 2003-425324	A1	20030429 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376708P	20020501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Karen S. Canady, Esq., Gates & Cooper LLP, Howard Hughes Center, 6701 Center Drive West, Suite 1050, Los Angeles, CA, 90045
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 2424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 17 USPATFULL on STN
TI Host cells containing multiple integrating vectors
AB The present invention relates to the production of proteins in host cells, and more particularly to host cells containing multiple integrated copies of an integrating vector. Suitable integrating vectors for use in the present invention include retrovirus vectors, lentivirus vectors, transposon vectors, and adeno-associated virus vectors. Methods are provided in which the host cells are prepared by using the integrating vectors at a high multiplicity of infection. The host cells are useful for producing pharmaceutical proteins, variants of proteins for use in screening assays, and for direct use in high throughput screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:134793 USPATFULL
TITLE: Host cells containing multiple integrating vectors
INVENTOR(S): Bremel, Robert D., Hillpoint, WI, UNITED STATES
Miller, Linda U., Lodi, WI, UNITED STATES
Bleck, Gregory T., Baraboo, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092882	A1	20030515

APPLICATION INFO.:	US 2001-897511	A1	20010629 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215925P	20000703 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105
NUMBER OF CLAIMS: 102
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Page(s)
LINE COUNT: 5628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 17 USPATFULL on STN
TI Lentiviral vectors encoding clotting factors for gene therapy
AB Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as **human** factor IX (hFIX) or **human** factor VIII (hFVIII) and can be used for treatment of hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:113079 USPATFULL
TITLE: Lentiviral vectors encoding clotting factors for gene therapy
INVENTOR(S): McArthur, James G., San Carlos, CA, UNITED STATES
Talbot, Dale John, San Francisco, CA, UNITED STATES
Simmons, Andrew D., San Mateo, CA, UNITED STATES
McGuinness, Ryan, Oakland, CA, UNITED STATES
Kelly, Michael, Carlsbad, CA, UNITED STATES
Tsui, Lisa V., Mountain View, CA, UNITED STATES
Dull, Thomas, San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003077812	A1	20030424	
APPLICATION INFO.:	US 2002-145289	A1	20020514	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-291083P	20010514 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER DRIVE WEST, SUITE 1050, LOS ANGELES, CA, 90045
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 17 USPATFULL on STN
TI Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
AB An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a

permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual. The vehicle is particularly well-suited to delivery of insulin from immunoisolated islets of Langerhans, and can also be used advantageously for delivery of high molecular weight products, such as products larger than IgG. A method of making a biocompatible, immunoisolatory implantable vehicle, consisting in a first embodiment of a coextrusion process, and in a second embodiment of a stepwise process. A method for isolating cells within a biocompatible, immunoisolatory implantable vehicle, which protects the isolated cells from attack by the immune system of an individual in whom the vehicle is implanted. A method of providing a needed biological product or metabolic function to an individual, comprising implanting into the individual an immunoisolatory vehicle containing isolated cells which produce the product or provide the metabolic function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:272488 USPATFULL
TITLE:	Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, UNITED STATES Emerich, Dwaine F., Providence, RI, UNITED STATES Hoffman, Diane, Cambridge, MA, UNITED STATES Sanberg, Paul R., Spring Hill, FL, UNITED STATES Christenson, Lisa, New Haven, CT, UNITED STATES Hegre, Orion D., Green Valley, AZ, UNITED STATES Scharp, David W., St. Louis, MO, UNITED STATES Lacy, Paul E., Webster Grove, MO, UNITED STATES Aebischer, Patrick, Lutry, SWITZERLAND Vasconcellos, Alfred V., Cranston, RI, UNITED STATES Lysaght, Michael J., E. Greenwich, RI, UNITED STATES Gentile, Frank T., Warwich, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150603	A1	20021017
APPLICATION INFO.:	US 2001-7344	A1	20011025 (10)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-563248, filed on 2 May 2000, GRANTED, Pat. No. US 6322804 Division of Ser. No. US 1998-148671, filed on 4 Sep 1998, GRANTED, Pat. No. US 6083523 Division of Ser. No. US 1995-449837, filed on 24 May 1995, GRANTED, Pat. No. US 5874099 Division of Ser. No. US 1994-179151, filed on 10 Jan 1994, GRANTED, Pat. No. US 5800828 Continuation-in-part of Ser. No. WO 1992-US3327, filed on 22 Apr 1992, UNKNOWN Continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, ABANDONED
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MINTZ LEVIN, One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS:	1
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Page(s)
LINE COUNT:	3733

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 17 USPATFULL on STN

TI Implantable biocompatible immunoisolatory vehicle for the delivery of selected therapeutic products

AB An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a

permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:214673 USPATFULL
TITLE:	Implantable biocompatible immunoisolatory vehicle for the delivery of selected therapeutic products
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, United States Emerich, Dwaine F., Providence, RI, United States Hoffman, Diane, Cambridge, MA, United States Sanberg, Paul R., Spring Hill, FL, United States Christenson, Lisa, New Haven, CT, United States Hegre, Orion D., Green Valley, AZ, United States Scharp, David W., St. Louis, MO, United States Lacy, Paul E., Webster Grove, MO, United States Aebischer, Patrick, Lutry, Switzerland Vasconcellos, Alfred V., Cranston, RI, United States Lysaght, Michael J., E. Greenwich, RI, United States Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S):	Neurotech S.A., Evry, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6322804	B1	20011127
APPLICATION INFO.:	US 2000-563248		20000502 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-148671, filed on 4 Sep 1998, now patented, Pat. No. US 6083523 Division of Ser. No. US 1995-449837, filed on 24 May 1995, now patented, Pat. No. US 5874099 Division of Ser. No. US 179151, now patented, Pat. No. US 5800828 Continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Bawa, Raj
LEGAL REPRESENTATIVE:	Mintz, Levin, Cohn, Ferris, Glovsky and Pope, P.C., Elrifi, Ivor R., Karnakis, Christina V.
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	3794

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 17 USPATFULL on STN

TI Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products

AB An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:83864 USPATFULL
TITLE:	Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, United States Emerich, Dwaine F., Providence, RI, United States Hoffman, Diane, Cambridge, MA, United States Sanberg, Paul R., Spring Hill, FL, United States Christenson, Lisa, New Haven, CT, United States

	Hegre, Orion D., Green Valley, AZ, United States Scharp, David W., St. Louis, MO, United States Lacy, Paul E., Webster Grove, MO, United States Aebischer, Patrick, Lutry, Switzerland Vasconcellos, Alfred V., Cranston, RI, United States Lysaght, Michael J., Greenwich, RI, United States Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S):	Brown University Research Foundation, Providence, RI, United States (U.S. corporation) Brown University, Providence, RI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6083523		20000704
APPLICATION INFO.:	US 1998-148671		19980904 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-449837, filed on 24 May 1995, now patented, Pat. No. US 5874099 And a continuation-in-part of Ser. No. WO 1992-US3327, filed on 22 Apr 1992 which is a continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Azpuru, Carlos A.
LEGAL REPRESENTATIVE:	Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., Elrifi, Ivor R., Prince, John
NUMBER OF CLAIMS:	40
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	3880

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 17 USPATFULL on STN

TI Promiscuous G-protein compositions and their use

AB Disclosed are compositions and methods for their use, such as in identifying G-protein coupled receptors and ligands and compounds that modulate signal transduction. The compositions and methods employ promicuous G-proteins. Activation of the promiscous G-protein can be detected in a variety of assays, including assays in which activation is indicated by a change in fluorescence emission of a sample that contains the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:166849 USPATFULL
TITLE:	Promiscuous G-protein compositions and their use
INVENTOR(S):	Negulescu, Paul, Solana Beach, CA, United States Offermanns, Stefan, Berlin, Germany, Federal Republic of Simon, Melvin, San Marino, CA, United States Zuker, Charles, San Diego, CA, United States
PATENT ASSIGNEE(S):	Aurora BioSciences Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004808		19991221
APPLICATION INFO.:	US 1997-878801		19970619 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20234P	19960621 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Achutamurthy, Ponnathapu

ASSISTANT EXAMINER: Mayhew, Bradley S.
LEGAL REPRESENTATIVE: Gary Cary Ware & Freidenrich LLP, Haile, Lisa A.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 17 USPATFULL on STN
TI Recombinant DNA molecules and expression vectors for tissue plasminogen activator
AB A recombinant DNA molecule adapted for transfection of a host cell comprising a nucleic acid molecule encoding mammalian erythropoietin or tissue plasminogen activator, an expression control sequence operatively linked thereto and at least one SAR element. The invention also relates to expression vectors having the recombinant DNA molecule and to mammalian cells transformed with the expression vector. The mammalian cells lack multiple copies of an amplified amplification gene and are capable of expressing recombinant EPO or tPA in vitro at levels of at least 1,500 u or 500 u/10.sup.6 cells in 24 hours respectively. The invention further relates to a method of expressing recombinant mammalian EPO or tPA using the expression vectors and to a transgenic non-human animal or embryo whose germ cells and somatic cells contain a DNA construct having the recombinant DNA molecule of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:146307 USPATFULL
TITLE: Recombinant DNA molecules and expression vectors for tissue plasminogen activator
INVENTOR(S): Delcuve, Genevieve, Winnipeg, Canada
Awang, Gregor, Winnipeg, Canada
PATENT ASSIGNEE(S): Cangene Corporation, Winnipeg, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5985607		19991116
APPLICATION INFO.:	US 1997-883795		19970627 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-358918, filed on 19 Dec 1994, now patented, Pat. No. US 5888774
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bereskin & Parr
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 17 USPATFULL on STN
TI Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core
AB A method of forming an implantable and retrievable immunoisolatory vehicles is disclosed, the method comprising the steps of first forming a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells capable of providing a biologically active product or metabolic or immunologic function, said cells being dispersed in a biocompatible hydrogel or extracellular matrix, and then forming around the core a surrounding external biocompatible thermoplastic or hydrogel jacket free of said cells projecting externally thereof, said jacket having molecular weight cutoff permitting passage of molecules to and from the

core through said jacket to provide said biologically active product or function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:24325 USPATFULL
TITLE:	Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, United States Emerich, Dwaine F., Providence, RI, United States Hoffman, Diane, Cambridge, MA, United States Sanberg, Paul R., Spring Hill, FL, United States Christenson, Lisa, New Haven, CT, United States Hegre, Orion D., Green Valley, AZ, United States Scharp, David W., St. Louis, MO, United States Lacy, Paul E., Webster Grove, MO, United States Aebischer, Patrick, Lutry, Switzerland Vasoohcellos, Alfred V., Cranston, RI, United States Lysaght, Michael J., E. Greenwich, RI, United States Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S):	Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5874099		19990223
APPLICATION INFO.:	US 1995-449837		19950524 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-179151, filed on 10 Jan 1994 which is a continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Bawa, Raj
LEGAL REPRESENTATIVE:	Elrifi, Ivor R.Mitz, Levin
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	3
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	3879

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 17 USPATFULL on STN

TI Methods for treatment or prevention of neurodegenerative conditions using immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core

AB A method for treatment of a neurodegenerative condition in a patient comprising implanting in the patient at least one immunoisolatory vehicle comprising a corc comprising a volume of at least 1 .mu.l and at least 10.sup.4 living cells which secrete at least one biologically active product, said cells being dispersed in a biocompatible matrix comprising a hydrogel or extracellular matrix components, and an external jacket surrounding the core, the jacket comprising a biocompatible hydrogel or thermoplastic, the jacket being free of cells projecting externally thereof, said jacket having a molecular weight cutoff permitting the passage of the biologically active product from the core through the jacket.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:21753 USPATFULL
TITLE:	Methods for treatment or prevention of neurodegenerative conditions using immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, United States Emerich, Dwaine F., Providence, RI, United States

Hoffman, Diane, Cambridge, MA, United States
Sanberg, Paul R., Spring Hill, FL, United States
Christenson, Lisa, New Haven, CT, United States
Hegre, Orion D., Green Valley, AZ, United States
Scharp, David W., St. Louis, MO, United States
Lacy, Paul E., Webster Grove, MO, United States
Aebischer, Patrick, Lutry, Switzerland
Vasconcellos, Alfred V., Cranston, RI, United States
Lysaght, Michael J., E. Greenwich, RI, United States
Gentile, Frank T., Warwich, RI, United States

PATENT ASSIGNEE(S): Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5871767		19990216
APPLICATION INFO.:	US 1995-449062		19950524 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-179151, filed on 10 Jan 1994 which is a continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Ekrufu, Ivor R.Mintz, Levin
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 3909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 17 USPATFULL on STN

TI Methods for treating diabetes by delivering insulin from biocompatible cell-containing devices

AB A method for treating diabetes in a patient comprising subcutaneously implanting in the patient at least one immunoisolatory vehicle comprising a core comprising a volume of at least 1 .mu.l and at least about 10.sup.4 living cells which secrete insulin, said cells being dispersed in a biocompatible matrix comprising a hydrogel or extracellular matrix components, and a surrounding external jacket of a biocompatible thermoplastic or hydrogel free of said cells projecting externally thereof, said jacket being permselective and immunoisolatory, said jacket having a molecular weight cutoff permitting passage of molecules between the patient and core through said jacket wherein the insulin is released from the immunoisolatory vehicle into the patient's body to treat diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:18748 USPATFULL
TITLE: Methods for treating diabetes by delivering insulin from biocompatible cell-containing devices

INVENTOR(S): Dionne, Keith E., Rehoboth, MA, United States
Emerich, Dwaine F., Providence, RI, United States
Hoffman, Diane, Cambridge, MA, United States
Sanberg, Paul R., Spring Hill, FL, United States
Christenson, Lisa, New Haven, CT, United States
Hegre, Orion D., Green Valley, AZ, United States
Scharp, David W., St. Louis, MO, United States
Lacy, Paul E., Webster Grove, MO, United States
Aebischer, Patrick, Lutry, Switzerland
Vasconcellos, Alfred V., Cranston, RI, United States
Lysaght, Michael J., Greenwich, RI, United States
Gentile, Frank T., Warwich, RI, United States

PATENT ASSIGNEE(S): Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869077		19990209
APPLICATION INFO.:	US 1995-449562		19950524 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-179151, filed on 10 Jan 1994 which is a continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Elrifi, Ivor R.Mintz, Levin
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 3813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 17 USPATFULL on STN

TI Methods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix core

AB A method of forming an implantable and retrievable immunoisolatory vehicle is disclosed, the method comprising the steps of first forming a jacket of biocompatible thermoplastic or hydrogel, and then loading the jacket with a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells capable of secreting a biocompatible matrix comprising a hydrogel or extracellular matrix, said jacket having a molecular weight cutoff permitting passage of molecules thereacross to provide said biologically active product or said function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:138453 USPATFULL
TITLE: Methods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix core

INVENTOR(S): Dionne, Keith E., Rehoboth, MA, United States
Emerich, Dwaine F., Providence, RI, United States
Hoffman, Diane, Cambridge, MA, United States
Sanberg, Paul R., Spring Hill, FL, United States
Christenson, Lisa, New Haven, CT, United States
Hegre, Orion D., Green Valley, AZ, United States
Sharp, David W., St. Louis, MO, United States
Lacy, Paul E., Webster Grove, MO, United States
Aebischer, Patrick, Lutry, Switzerland
Vasconcellos, Alfred V., Cranston, RI, United States
Lysaght, Michael J., Greenwich, RI, United States
Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S): Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834001		19981110
APPLICATION INFO.:	US 1995-449214		19950524 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-179151, filed on 10 Jan 1994 which is a continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Ivor Elrifi Mintz, Levin
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 5
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)

LINE COUNT: 3844
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 17 USPATFULL on STN
TI Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
AB A method of making an immunoisolatory vehicle comprised of a core comprising living cells dispersed in a biocompatible matrix is disclosed, the cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to an individual, and an external jacket surrounding said core which is a biocompatible, permselective thermoplastic or hydrogel, said jacket being free of said cells, comprising coextruding a suspension comprising said cells dispersed in a precursor matrix material comprising extracellular matrix components or a biocompatible hydrogel precursor, and a solution of a biocompatible jacket precursor from a nested dual-bore extrusion nozzle, wherein the suspension of (a) is coextruded from the inner bore and the solution of (b) is coextruded from the outer bore of the nozzle, to form said jacket as the solution of (b) and the suspension of (a) arc coextruded; and exposing the vehicle to a treatment that forms a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells and comprising a biocompatible matrix from the precursor matrix of solution (a).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:104405 USPATFULL
TITLE: Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
INVENTOR(S): Dionne, Keith E., Rehoboth, MA, United States
Emerich, Dwaine F., Providence, RI, United States
Hoffman, Diane, Cambridge, MA, United States
Sanberg, Paul R., Spring Hill, FL, United States
Christenson, Lisa, New Haven, CT, United States
Hegre, Orion D., Green Valley, AZ, United States
Scharp, David W., St. Louis, MO, United States
Lacy, Paul E., Webster Grove, MO, United States
Aebischer, Patrick, Lutry, Switzerland
Vasconcellos, Alfred V., Cranston, RI, United States
Lysaght, Michael J., E. Greenwich, RI, United States
Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S): Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5800829		19980901
APPLICATION INFO.:	US 1995-449274		19950524 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-179151, filed on 10 Jan 1994 which is a continuation-in-part of Ser. No. US 1991-693403, filed on 25 Apr 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Elrifi, Ivor R.Mintz, Levin
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 6
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 3898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 17 USPATFULL on STN
TI Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products

AB Immunoisolatory vehicles having a core and a surrounding jacket are disclosed, the core having a volume in excess of 1 .mu.l and at least about 10.sup.4 living cells capable of secreting a biologically active product or of providing a biological function to a patient, the cells dispersed in a biocompatible matrix formed of a hydrogel or an extracellular matrix component, and the external jacket being permselective, biocompatible and having a molecular weight cutoff permitting passage of molecules between the patient and the core through said jacket to provide said biological product or function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:104404 USPATFULL
TITLE:	Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, United States Emerich, Dwaine F., Providence, RI, United States Hoffman, Diane, Cambridge, MA, United States Sanberg, Paul R., Spring Hill, FL, United States Christenson, Lisa, New Haven, CT, United States Hegre, Orion D., Green Valley, AZ, United States Scharp, David W., St. Louis, MO, United States Lacy, Paul E., Webster Grove, MO, United States Aebischer, Patrick, Lutry, Switzerland Vasconcellos, Alfred V., Cranston, RI, United States Lysaght, Michael J., E. Greenwich, RI, United States Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S):	Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5800828		19980901
APPLICATION INFO.:	US 1994-179151		19940110 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Bawa, Raj
LEGAL REPRESENTATIVE:	Elrifi, Ivor R.Mintz, Levin
NUMBER OF CLAIMS:	43
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	3914

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 17 USPATFULL on STN

TI Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products

AB A method of providing a biologically active molecule or metabolic or immunologic function to a patient, comprising implanting into the body of the patient at least one immunoisolatory vehicle comprising a core comprising a volume in excess of 1 .mu.l and at least about 10.sup.4 living cells dispersed in a biocompatible matrix formed of a hydrogel or extracellular matrix components, said cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to the patient; and an external jacket surrounding said core, said jacket being formed from a thermoplastic or hydrogel, said jacket being free of said cells projecting externally therefrom, said jacket being biocompatible and having a molecular weight cutoff permitting passage of molecules between the patient and the core through said jacket to provide said biologically active product of function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:101409 USPATFULL

TITLE:	Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
INVENTOR(S):	Dionne, Keith E., Rehoboth, MA, United States Emerich, Dwaine F., Providence, RI, United States Hoffman, Diane, Cambridge, MA, United States Sanberg, Paul R., Spring Hill, FL, United States Christenson, Lisa, New Haven, CT, United States Hegre, Orion D., Green Valley, AZ, United States Scharp, David W., St. Louis, MO, United States Lacy, Paul E., Webster Grove, MO, United States Aebischer, Patrick, Lutry, Switzerland Vasooncellos, Alfred V., Cranston, RI, United States Lysaght, Michael J., Greenwich, RI, United States Gentile, Frank T., Warwich, RI, United States
PATENT ASSIGNEE(S):	Brown University Research Foundation, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5798113		19980825
APPLICATION INFO.:	US 1995-449524		19950524 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-179151, filed on 10 Jan 1994 which is a continuation-in-part of Ser. No. US 1991-692403, filed on 25 Apr 1991, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Bawa, Raj
LEGAL REPRESENTATIVE:	Elrifi, Ivor R., Levin, Mintz
NUMBER OF CLAIMS:	33
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	3901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 17 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

TI Methods for increasing the efficiency of recombinant AAV product.

AB The present invention relates to methods and compositions for increasing the production of high titre stocks of recombinant AAV (rAAV) through regulation of expression of the AAV REP and CAP proteins. The methods and compositions of the invention are based on the observation that the low level expression of the AAV REP protein increases the production of AAV viral capsid protein and efficiency of packaging resulting in production of higher titre recombinant viral stocks. The invention encompasses recombinant AAV vectors that direct the expression of AAV REP and CAP proteins and the use of such vectors for the production of novel stable cell lines capable of generating high titre rAAV vectors. The invention provides methods for regulating the expression of the AAV REP gene at the transcriptional and post-translational level. The methods and compositions of the invention can be used to produce high titre stocks of rAAV which can be used in gene therapy for the purpose of transferring genetic information into appropriate host cells for the management and correction of human diseases including inherited and acquired disorders.

ACCESSION NUMBER:	2003:227284 BIOSIS
DOCUMENT NUMBER:	PREV200300227284
TITLE:	Methods for increasing the efficiency of recombinant AAV product.
AUTHOR(S):	Samulski, Richard Jude [Inventor, Reprint Author]; Xiao, Xiao [Inventor]; Snyder, Richard [Inventor]
CORPORATE SOURCE:	Wexford, PA, USA ASSIGNEE: Cell Genesys, Inc.; The University of North Carolina at Chapel Hill
PATENT INFORMATION:	US 6548286 April 15, 2003
SOURCE:	Official Gazette of the United States Patent and Trademark

Office Patents, (Apr. 15, 2003) Vol. 1269, No. 3.
http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133 (ISSN print).

DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 7 May 2003
Last Updated on STN: 7 May 2003

```
=> e cho, M/au
E1            1     CHO ZUITO/AU
E2            1     CHO ZUIZEN/AU
E3            0 --> CHO, M/AU
E4            1     CHOA/AU
E5            1     CHOA A J O/AU
E6            1     CHOA A K/AU
E7            1     CHOA A K H/AU
E8            4     CHOA B/AU
E9            8     CHOA B H G/AU
E10           3     CHOA C/AU
E11           1     CHOA C C/AU
E12           2     CHOA C G/AU

=> e chan, s/au
E1            1     CHAN ZUY KHUONG/AU
E2            1     CHAN ZYU KHUONG/AU
E3            0 --> CHAN, S/AU
E4            1     CHANA/AU
E5           14     CHANA A/AU
E6            2     CHANA A K/AU
E7            1     CHANA A S/AU
E8            3     CHANA ANTONIA/AU
E9           12     CHANA ANTONIO/AU
E10           7     CHANA B S/AU
E11           2     CHANA C/AU
E12           3     CHANA C H/AU

=> e kelsey, W/au
E1            6     KELSEY Z/AU
E2            1     KELSEY ZOE/AU
E3            0 --> KELSEY, W/AU
E4            1     KELSEYFRY I/AU
E5            1     KELSEYGC/AU
E6           15     KELSH D J/AU
E7            7     KELSH DENNIS J/AU
E8            1     KELSH DENNIS JOSEPH/AU
E9            1     KELSH DENNNIS J/AU
E10           2     KELSH H K/AU
E11           9     KELSH J M/AU
E12           1     KELSH J P/AU

=> e yee, H/au
E1            1     YEE Z Z/AU
E2            1     YEE ZHON ZHUN/AU
E3            0 --> YEE, H/AU
E4            2     YEEBIYO Y/AU
E5            2     YEEBRADBURY C/AU
E6            1     YEEBRADBURY C M/AU
E7            1     YEECHAUNG S/AU
E8            1     YEECHIEN L/AU
E9            2     YEECHONG H/AU
E10           1     YEED H/AU
E11           2     YEEDA DAVID/AU
E12           1     YEEDA MASAYUKI/AU
```